Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
| Authors | Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, Anna-Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Julia Von Tresckow, Christian Maurer, Nadine Kutsch, Manuela Hoechstetter, Martin Dreyling, Elisabeth Lange, Michael Kneba, Stephan Stilgenbauer, Hartmut Döhner, Manfred Hensel, Michael G Kiehl, Ulrich Jaeger, Clemens-Martin Wendtner, Valentin Goede, Kirsten Fischer, Michael von Bergwelt-Baildon, Barbara Eichhorst, Michael Hallek, Sebastian Theurich |
| Journal | Leukemia
(Leukemia)
Vol. 34
Issue 4
Pg. 1177-1181
(04 2020)
ISSN: 1476-5551 [Electronic] England |
| PMID | 31728057
(Publication Type: Letter, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Rituximab
- Bendamustine Hydrochloride
- Vidarabine
|
| Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bendamustine Hydrochloride
(administration & dosage)
- Clinical Trials, Phase III as Topic
- Female
- Follow-Up Studies
- Humans
- Immunotherapy
(mortality)
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, mortality, pathology)
- Male
- Middle Aged
- Obesity
(physiopathology)
- Prognosis
- Prospective Studies
- Rituximab
(administration & dosage)
- Sex Factors
- Survival Rate
- Vidarabine
(administration & dosage)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
